BridgeBio Q3 operating expense down 26% vs Q1 2022; positive Phase 2 data for BBP-418 and infigratinib

BridgeBio Pharma, Inc.

2022-Q3 EPS reported -$2.34 revenue$75,778,000

Q3 operating costs $129.5M, down 26.2% from Q1 2022; net loss $137.3M vs $155.9M prior year.
Cash, equivalents and marketable securities $558.3M, providing runway into 2024.
BBP-418 12-month Phase 2: αDG glycosylation +0.21 at day 90, >75% creatine kinase reduction, no SAEs.
Low-dose infigratinib Phase 2 Cohort 5 enrolled with no SAEs; AHV update in H1 2023, Phase 3 planned.
First patient dosed in Phase 1/2 of BBP-398 plus Amgen's Lumakras for KRAS G12C; FDA Fast Track granted.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BridgeBio Pharma, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

BridgeBio Pharma, Inc. (the “Company”) reported recent business updates and its financial results for the third quarter ended September 30, 2022.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-277008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.